Medicare Enrolled
Dr. Ibrahim Sbeitan, MD
Hematology & Oncology · Johnstown, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sbeitan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sbeitan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sbeitan
Dr. Ibrahim Sbeitan is a hematology & oncology specialist in Johnstown, PA, with 21 years of NPI registration. Based on federal Medicare data, Dr. Sbeitan performed 21,716 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Sbeitan received a total of $11,108 from 67 pharmaceutical and/or device companies across 485 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sbeitan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 21 years of NPI registration
▲ Top 16% volume in PA
$11,108 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗21,716
Medicare services
Top 16% in PA for hematology & oncology
Not available
Unique patients (not deduplicated)
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
12,750 | $1 | $3 |
| Denosumab injection (Prolia/Xgeva) | 2,460 | $18 | $35 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,820 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 940 | $1 | $45 |
| Anti-nausea injection (ondansetron/Zofran) | 864 | $0 | $1 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
609 | $90 | $209 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
348 | $132 | $283 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
315 | $12 | $51 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
312 | $99 | $256 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
269 | $11 | $49 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
236 | $22 | $59 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
123 | $1 | $3 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
102 | $4 | $11 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
95 | $55 | $141 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
92 | $49 | $119 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
70 | $18 | $47 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
64 | $49 | $131 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
61 | $62 | $143 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
34 | $92 | $206 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
33 | $42 | $160 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
32 | $55 | $142 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
32 | $102 | $271 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $130 | $322 |
| New patient office visit, complex (60-74 min) | 26 | $156 | $405 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
62.0% high complexity
32.3% medium
5.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,108
Total received (2018-2024)
Avg $1,587/year across 7 years
Top 21% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
67
Companies
485
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,314
2023
$1,987
2022
$1,582
2021
$2,109
2020
$430
2019
$2,316
2018
$1,371
Payments by company (2024)
Astellas Pharma US Inc
$267
Daiichi Sankyo Inc.
$151
E.R. Squibb & Sons, L.L.C.
$101
Janssen Biotech, Inc.
$100
Novartis Pharmaceuticals Corporation
$92
Lilly USA, LLC
$75
PFIZER INC.
$72
Incyte Corporation
$57
BeiGene USA, Inc.
$51
AstraZeneca Pharmaceuticals LP
$47
Coherus Biosciences Inc.
$37
ARRAY BIOPHARMA INC
$32
Regeneron Healthcare Solutions, Inc.
$30
ABBVIE INC.
$25
GlaxoSmithKline, LLC.
$22
Genentech USA, Inc.
$21
Genmab U.S., Inc.
$18
Eisai Inc.
$16
ADC Therapeutics America, Inc.
$16
Celgene Corporation
$16
Merck Sharp & Dohme LLC
$15
Kite Pharma, Inc.
$14
SERVIER PHARMACEUTICALS LLC
$14
Gilead Sciences, Inc.
$13
Octapharma USA, Inc.
$13
Top 3 companies account for 39.5% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$2,308
Taiho Oncology, Inc.
$1,159
Astellas Pharma US Inc
$656
AstraZeneca Pharmaceuticals LP
$580
Lilly USA, LLC
$547
Celgene Corporation
$438
Novartis Pharmaceuticals Corporation
$438
Incyte Corporation
$359
PFIZER INC.
$358
Takeda Pharmaceuticals U.S.A., Inc.
$316
BeiGene USA, Inc.
$281
Genentech USA, Inc.
$277
Janssen Biotech, Inc.
$276
Pharmacyclics LLC, An AbbVie Company
$224
Kite Pharma, Inc.
$220
Daiichi Sankyo Inc.
$203
GlaxoSmithKline, LLC.
$183
EISAI INC.
$171
Amgen Inc.
$160
Eisai Inc.
$118
Exelixis Inc.
$116
Merck Sharp & Dohme Corporation
$110
Foundation Medicine, Inc.
$109
Bayer HealthCare Pharmaceuticals Inc.
$101
Secura Bio, Inc.
$84
Seagen Inc.
$76
EMD Serono, Inc.
$73
GENZYME CORPORATION
$65
AbbVie Inc.
$63
Coherus Biosciences Inc.
$53
ARRAY BIOPHARMA INC
$46
Medtronic USA, Inc.
$45
Merck Sharp & Dohme LLC
$42
Boehringer Ingelheim Pharmaceuticals, Inc.
$42
Gilead Sciences, Inc.
$41
Seattle Genetics, Inc.
$40
TESARO, Inc.
$39
CTI BioPharma Corp.
$35
Karyopharm Therapeutics Inc.
$34
Ipsen Biopharmaceuticals, Inc
$34
Stryker Corporation
$32
Aurobindo Pharma USA, Inc.
$32
Regeneron Healthcare Solutions, Inc.
$30
Myriad Genetic Laboratories, Inc.
$30
PharmaEssentia USA Corporation
$29
ADC Therapeutics America, Inc.
$29
AbbVie, Inc.
$27
Clovis Oncology, Inc.
$27
Acrotech Biopharma LLC
$26
ABBVIE INC.
$25
MEDIVATION FIELD SOLUTIONS LLC
$23
G1 Therapeutics, Inc.
$23
Advanced Accelerator Applications
$22
Pharmacyclics LLC, an AbbVie Company
$22
ASD SPECIALTY HEALTHCARE, LLC
$20
Pharmacosmos Therapeutics Inc.
$18
Genmab U.S., Inc.
$18
Alexion Pharmaceuticals, Inc.
$18
TAIHO ONCOLOGY, INC.
$18
Acceleron Pharma, Inc.
$17
Myovant Sciences Inc.
$17
Helsinn Therapeutics (U.S.), Inc.
$16
Puma Biotechnology, Inc.
$15
Novocure Inc.
$14
SERVIER PHARMACEUTICALS LLC
$14
Octapharma USA, Inc.
$13
Array BioPharma Inc.
$12
Top 3 companies account for 37.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKEEGA · AKYNZEO · ALUNBRIG · AUGTYRO · Abraxane · Alecensa · Aliqopa · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Beleodaq · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Enhertu · FARYDAK · FASLODEX · FOUNDATIONONE · GAZYVA · GILOTRIF · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LARTRUVO · LIBTAYO · LONSURF · LORBRENA · LUTATHERA (lutetium Lu 177 dotatate) · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MVASI · Marqibo · NINLARO · Nerlynx · Neulasta · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · OPDIVO · OPDUALAG · OPTABLATE · ORGOVYX · OSTEOCOOL RF ABLATION · Oncology · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PRECISETUMOR · PROMACTA · Perjeta · Pomalyst · REBLOZYL · RETEVMO · RYBREVANT · Reblozyl · Revlimid · Rubraca · SANDOSTATIN LAR · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TUKYSA · Tibsovo · Tivdak · Udenyca · VELCADE · VENCLEXTA · VERZENIO · VOTRIENT · Vanflyta · Venclexta · Vonjo · XALKORI · XOSPATA · XPOVIO · XTANDI · Xofigo · Xtandi · Yescarta · ZEJULA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
7
County median income
$56,292
Nearest hospital to ZIP centroid (approximate)
CONEMAUGH MEMORIAL MEDICAL CENTER
4.0 mi
4.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sbeitan is a mixed practice specialist, with above-average Medicare volume (top 16% in PA), with 21 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sbeitan experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Sbeitan performed 12,750 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Sbeitan receive payments from pharmaceutical companies?
Yes. Dr. Sbeitan received a total of $11,108 from 67 companies across 485 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sbeitan's costs compare to other hematology & oncology specialists in Johnstown?
Dr. Sbeitan's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sbeitan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Johnstown
Browse hematology & oncology specialists in Johnstown ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Taiho Oncology, Inc. Payments to Doctors
See all physicians who received payments from Taiho Oncology, Inc.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology